Effectiveness, safety and cost-effectiveness of vaporized nicotine products versus nicotine replacement therapy for tobacco smoking cessation in a low-socioeconomic status Australian population: a study protocol for a randomized controlled trial.
Cost-effectiveness
Electronic cigarettes
Randomized controlled trial
Smoking cessation
Social disadvantage
Tobacco
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
14 Sep 2022
14 Sep 2022
Historique:
received:
19
05
2022
accepted:
06
08
2022
entrez:
14
9
2022
pubmed:
15
9
2022
medline:
17
9
2022
Statut:
epublish
Résumé
In Australia, tobacco smoking rates have declined but inequalities remain with significantly higher smoking prevalence among low-socioeconomic populations. Clinical trial data suggest vaporized nicotine products (VNPs) aid smoking cessation. Most VNP trials have used refillable tank systems, but newer generation (pod) devices now comprise the largest market share yet have limited clinical trial evidence on safety and effectiveness. This study evaluates the effectiveness, safety and cost-effectiveness of VNPs (pod and tank device) compared with nicotine replacement therapy ([NRT]-gum or lozenge) for smoking cessation. This is a two-arm, open-label, superiority, parallel group, randomized controlled trial (RCT) with allocation concealment and blinded outcome assessment. The RCT is conducted at the National Drug and Alcohol Research Centre at the University of New South Wales, Sydney, Australia. Participants are people who smoke daily, are interested in quitting and receive a government pension or allowance (N = 1058). Participants will be randomized (1:1 ratio) to receive 8 weeks of free: VNPs, with pod (40 mg/mL nicotine salt) and tank device (18 mg/mL freebase nicotine) in mixed flavours; or NRT (gum or lozenge; 4 mg). All participants will receive daily text message behavioural support for 5 weeks. Assessments will be undertaken by telephone at baseline, with three follow-up calls (two check-in calls within the first month and final follow-up at 7 months post randomization) to ascertain smoking status, treatment adherence and adverse events. The primary outcome is 6-month continuous abstinence verified by carbon monoxide breath test of ≤5ppm at 7-month follow-up. Safety and cost-effectiveness of VNPs versus NRT will also be evaluated. Further data are required to strengthen certainty of evidence for VNPs aiding smoking cessation, particularly for newer generation pod devices. To our knowledge, this trial is the first to offer choice of VNPs and no comparative effectiveness trial data exists for new pod devices. If effective, the findings can inform wider implementation of VNPs to aid smoking cessation in a priority group. Australian New Zealand Clinical Trials Registry ACTRN12621000076875. Registered on 29 January 2021. https://www.anzctr.org.au.
Sections du résumé
BACKGROUND
BACKGROUND
In Australia, tobacco smoking rates have declined but inequalities remain with significantly higher smoking prevalence among low-socioeconomic populations. Clinical trial data suggest vaporized nicotine products (VNPs) aid smoking cessation. Most VNP trials have used refillable tank systems, but newer generation (pod) devices now comprise the largest market share yet have limited clinical trial evidence on safety and effectiveness. This study evaluates the effectiveness, safety and cost-effectiveness of VNPs (pod and tank device) compared with nicotine replacement therapy ([NRT]-gum or lozenge) for smoking cessation.
METHODS
METHODS
This is a two-arm, open-label, superiority, parallel group, randomized controlled trial (RCT) with allocation concealment and blinded outcome assessment. The RCT is conducted at the National Drug and Alcohol Research Centre at the University of New South Wales, Sydney, Australia. Participants are people who smoke daily, are interested in quitting and receive a government pension or allowance (N = 1058). Participants will be randomized (1:1 ratio) to receive 8 weeks of free: VNPs, with pod (40 mg/mL nicotine salt) and tank device (18 mg/mL freebase nicotine) in mixed flavours; or NRT (gum or lozenge; 4 mg). All participants will receive daily text message behavioural support for 5 weeks. Assessments will be undertaken by telephone at baseline, with three follow-up calls (two check-in calls within the first month and final follow-up at 7 months post randomization) to ascertain smoking status, treatment adherence and adverse events. The primary outcome is 6-month continuous abstinence verified by carbon monoxide breath test of ≤5ppm at 7-month follow-up. Safety and cost-effectiveness of VNPs versus NRT will also be evaluated.
DISCUSSION
CONCLUSIONS
Further data are required to strengthen certainty of evidence for VNPs aiding smoking cessation, particularly for newer generation pod devices. To our knowledge, this trial is the first to offer choice of VNPs and no comparative effectiveness trial data exists for new pod devices. If effective, the findings can inform wider implementation of VNPs to aid smoking cessation in a priority group.
TRIAL REGISTRATION
BACKGROUND
Australian New Zealand Clinical Trials Registry ACTRN12621000076875. Registered on 29 January 2021. https://www.anzctr.org.au.
Identifiants
pubmed: 36104702
doi: 10.1186/s13063-022-06644-8
pii: 10.1186/s13063-022-06644-8
pmc: PMC9473457
doi:
Substances chimiques
Nicotine
6M3C89ZY6R
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
777Subventions
Organisme : National Health and Medical Research Council
ID : APP1127390
Informations de copyright
© 2022. The Author(s).
Références
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
Addiction. 2020 Jun;115(6):1141-1148
pubmed: 31994254
Thorax. 1999 Jul;54(7):581-6
pubmed: 10377201
PLoS One. 2013 Jun 24;8(6):e66317
pubmed: 23826093
J Gen Intern Med. 2014 Nov;29(11):1444-50
pubmed: 24830741
Am J Addict. 2015 Oct;24(7):607-12
pubmed: 26408249
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Nicotine Tob Res. 2013 May;15(5):978-82
pubmed: 22990219
Int J Environ Res Public Health. 2015 Jun 08;12(6):6403-22
pubmed: 26062037
Psychopharmacology (Berl). 2004 Dec;177(1-2):195-9
pubmed: 15179542
Addiction. 2016 Mar;111(3):535-44
pubmed: 26430813
Drug Alcohol Depend. 2014 Oct 1;143:158-66
pubmed: 25156228
Drug Alcohol Depend. 2013 Dec 1;133(2):740-5
pubmed: 24075070
Psychopharmacology (Berl). 2017 Mar;234(5):773-779
pubmed: 28070620
Psychol Addict Behav. 2009 Mar;23(1):56-66
pubmed: 19290690
Psychopharmacology (Berl). 2014 Jan;231(2):401-7
pubmed: 23978909
Lancet. 2013 Nov 16;382(9905):1629-37
pubmed: 24029165
Sci Rep. 2014 Feb 26;4:4133
pubmed: 24569565
Addiction. 2005 Mar;100(3):299-303
pubmed: 15733243
Stat Methods Med Res. 1998 Jun;7(2):187-203
pubmed: 9654641
Nicotine Tob Res. 2018 Feb 7;20(3):276-285
pubmed: 28034998
Addiction. 2006 Jan;101(1):121-7
pubmed: 16393198
Addict Behav. 2017 Jan;64:13-20
pubmed: 27533077
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
Clin Respir J. 2016 Mar;10(2):168-75
pubmed: 25103370
BMJ. 2011 Feb 07;342:d40
pubmed: 21300711
Addict Behav. 2007 Jul;32(7):1451-60
pubmed: 17125931
Tob Control. 2017 Mar;26(e1):e23-e28
pubmed: 27729564
N Engl J Med. 2019 Feb 14;380(7):629-637
pubmed: 30699054
Cochrane Database Syst Rev. 2021 Apr 29;4:CD010216
pubmed: 33913154
Tob Control. 2010 Apr;19(2):98-103
pubmed: 20378585
JAMA. 2021 Jul 6;326(1):56-64
pubmed: 34228066
Int J Environ Res Public Health. 2014 Oct 29;11(11):11220-48
pubmed: 25358095
Tob Control. 2007 Apr;16(2):e2
pubmed: 17400932
Cochrane Database Syst Rev. 2019 Oct 22;10:CD006611
pubmed: 31638271
Psychol Med. 2002 Aug;32(6):959-76
pubmed: 12214795